1. Annual Medicaid Omnibus Legislation Overview (click here for more details)

Senate Bill 3365, the Illinois Fiscal Year 2027 Medicaid Omnibus, consolidated 23 individual legislative proposals into a single, cohesive framework, with a variety of health equity and patient-centered protections.

Even in the tight budget year, the fiscal scale of the package is significant, with a $113.8 million gross investment for FY27 ($56 million net state general revenue); however, the annualized cost jumps to $226.8 million gross ($109.1 million net) in FY28. This doubling reflects the long-term sustainability challenges the state faces.

A critical strategic component of SB3365 involves a ‘Safety-Net Paradox’, that while Illinois safety-net hospitals are reimbursed at 116% of their costs, structural misalignments and high fixed costs for emergency departments continue to trigger closures. To stabilize this infrastructure, the omnibus includes an $85 million Distressed Hospital Loan Program and $50 million in health care equity add-ons, aimed at bridging the gap between reimbursement rates and operational viability.

2. Clinical Mandates and Practice-Related Provisions

Specific Medicaid coverage mandates and related changes can often benefit family physicians by optimizing patient care pathways and eliminating financial barriers at the point of care. Understanding these requirements allows clinics to minimize administrative burdens and reduce financial friction for vulnerable populations.

The following table outlines several mandated Medicaid coverage areas as established in Senate Bill 3365, effective July 1, 2026:

• Preeclampsia Biomarker Testing

  • Advanced biomarker testing for predictive screening (asymptomatic) and management (symptomatic). Zero cost-sharing across all insurance types.

  • Immediate (Budget Neutral / Codification)

• Seizure Detection Devices

  • Coverage for medically prescribed, FDA-cleared technology. Cost-sharing is capped at $50 per plan year.

  • Effective FY28/29 (January 1, 2029)

• Sickle Cell Disease

  • Codifies medical assistance coverage to ensure long-term stability for specialized care.

  • Immediate (Codification of existing codes)

• Proteomic Blood Testing

  • Mandatory coverage for identifying and managing the risk of spontaneous preterm birth.

  • Immediate (Budget Neutral / Codification)

The primary benefit of codifying these services into the Public Aid Code is that it removes them from the category of ‘optional benefits’. Historically, optional benefits are the first to be cut during state budget cycles; by codifying these diagnostics, the legislature has provided statutory protection for these care pathways. Furthermore, because several of these items are ‘budget-neutral’ codifications of existing billing codes, the transition for practice billing workflows should be immediate and seamless, while eliminating the need for burdensome prior authorizations for previously ‘un-coded’ or optional procedures.

3. Behavioral Health Access and Administrative Reforms

Through the Medicaid omnibus legislation, effective July 1, 2026, the state is pursuing a strategic expansion of the behavioral health safety net, specifically utilizing telehealth parity to eliminate ‘service deserts’ in rural and underserved areas where in-person specialists are scarce.

• Telehealth Parity for Virtual IOP: Authorizes Medicaid coverage for virtual intensive outpatient programs (IOP), mandating reimbursement at the same rate as in-person care. This ensures that patient retention in mental health and addiction treatment remains high, regardless of transportation barriers.

• MCO Behavioral Health Integrity: To protect provider program integrity, the state is standardizing the guidance for Managed Care Organization (MCO) behavioral health reviews.

• The 72-Hour ‘Gold Card’ Rule Delay: Implementation of the ‘Gold Card’ program, which would exempt high-performing providers from prior authorization, is preserved but has been delayed to July 2027, with administrative rules expected to be proposed this summer, which IAFP will monitor for public comment.

4. The Impact of Federal HR 1 and Patient Coverage Risks

As state-level Medicaid legislation advanced this spring, federal policy under HR 1 continued to create new obstacles to patient continuity of care. The May 1st deadline for the expiration of federal grace periods represented an immediate ‘cliff’ for approximately half a million Illinois residents (click here for more details).

Strategic risks to family physician patient panels include:

• Mandatory Work Requirements: Non-disabled adults (ages 19–64) without dependents must now document 80 hours monthly of work, education, or volunteerism. The Illinois population subject to these rules has surged from 190,000 to 450,000 because the federal government removed longstanding age exemptions for those aged 55–64. Between 165,000 and 300,000 patients are at risk of disenrollment.

• Six-Month Eligibility Redeterminations: The shift from annual to semi-annual reviews doubles the administrative workload for patients and clinics, significantly increasing ‘paperwork burden’ where eligible patients lose coverage due to clerical hurdles.

• Reduction of Retroactive Medical Coverage: Retroactive coverage has been slashed from three months to one month for ACA adults (and two months for others). This creates an acute risk of uncompensated care for clinics if a patient seeks treatment shortly before a redetermination failure is discovered.

• Non-Citizen Eligibility: Starting October 2026, federal matching funds will be limited for certain immigrant categories (refugees/asylees). While state-level mitigation was proposed, it remains pending, leaving approximately 10,000 individuals at risk of losing coverage entirely.

Rural Health Transformation Program

Another important May date involved federal Rural Health Transformation Program (RHTP) funding, with Illinois awarded $193.4 million, of which $25 million began being assigned for planning grants in May to build administrative capacity at rural hospitals and clinics for the distribution of larger pools of funding in the future (click here for an RHTP infographic; click here for a podcast review of how Illinois compares to Midwest states).

Medical Education Affordability

Although not Medicaid-related, another aspect of HR1 impacting the future of family physicians were changes in student loan regulations and recent negotiated rulemaking. While nearly all aspects of this are federal policies, see AAFP Managing Student Loan Debt, they directly impact IAFP at the state level and related workforce-related initiatives, see e.g. Illinois Underserved Health Care Provider Workforce Program.

5. State Agency Mitigation and Infrastructure Investment

To counter the federal HR1 obstacles, DHS and HFS are pursuing a ‘spending to save’ strategy. The state is making a $50 million strategic investment to protect $700 million in SNAP federal revenue at risk due to an 11.56% administrative error rate, which directly correlates with Medicaid processing stability.

• Workforce Expansion ($40 Million): Funding for 450 new caseworkers specifically tasked with helping vulnerable populations, seniors, veterans, and the unhoused navigate the complex and more frequent documentation requirements.

• IT Infrastructure Upgrades ($10 Million): After a decade-long project for a claims processing system failed to fully deliver, the state is pivoting. This new investment automates income verification by connecting directly to the State Comptroller and Equifax, reducing manual entry errors and clerical disenrollments.

HFS has released a ‘Stakeholder Toolkit’ and will issue targeted 90-day notices to those impacted. As front-line advocates, IAFP members must encourage patients to update their contact information in the "Manage My Case" portal (abe.illinois.gov). State regulators highlight that correcting addresses can be a significant step to prevent eligible patients from losing coverage due to missed mail during the new, high-frequency redetermination cycles.

Beginning January 1, 2027, Family physicians may also see increased patient confusion and need regarding documentation of “medical frailty” exemptions to Medicaid work requirements due to medical frailty that ‘significantly limits’ a patients ability to meet work requirements; while this may be documented through self-attestation for the first year, starting in January 2028, states will be required to collect documentation for all exemptions (see “Medicaid work requirements threaten health coverage for millions” by AAFP, June 12, 2026).

For further information, HFS is conducting webinars this summer regarding the impact of HR 1; click here to register.

IAFP will continue to monitor these shifts, ensuring that administrative barriers do not compromise the clinical outcomes of patients.

1. 340B Drug Policy & The Transparency Compromise

The 340B drug pricing program serves as the essential cornerstone of the Illinois healthcare safety net, permitting providers to leverage federal discounts to maintain services for low-income and uninsured populations. However, spring legislative session tensions resulted in a critical regulatory pivot toward evidence-based oversight. For safety net hospitals, the debate is a matter of operational survival; for pharmaceutical manufacturers, it is a drive for fiscal accountability within an opaque system. This friction has forced a legislative compromise that moves beyond the status quo, prioritizing data collection as a prerequisite for future health policy infrastructure.

1.1 The Multi-Billion Dollar Legislative Standoff

The current policy environment is defined by a standoff between House Bill 2371 and House Bill 4327, representing a struggle over an estimated $2.5 billion in annual Illinois 340B revenue that currently lacks standardized state tracking. This lack of visibility is increasingly untenable given the national landscape; the 340B program saw a 23% national increase in value recently, expanding from $66.3 billion to $81.4 billion in a single year.

Hospitals and clinics championed HB 2371, effective upon being signed by the Governor this summer, the Patient Access to Pharmacy Protection Act, which seeks to safeguard contract pharmacy arrangements from manufacturer-imposed delivery restrictions. Proponents, including leaders from Mount Sinai Hospital, argued that capturing "the spread", the delta between discounted acquisition costs (which can fall to one cent) and commercial reimbursement, is the only way to fund non-billable care such as chemotherapy, adult dental, and food security programs.

In contrast, the pharmaceutical industry demanded more transparency through HB 4327, effective upon being signed by the Governor this summer. The pharmaceutical industry argued that the 340B program drifted from its safety net origins into a high-margin profit engine, citing that 340B brand drugs yield a 72% profit margin compared to standard margins of 3% to 4%. Pharmaceutical manufacturers contended that these margins frequently enrich third-party administrators rather than patients.

• Provider Objectives (Access)

  • Protect Contract Pharmacies: Prohibit delivery restrictions to ensure patients can access drugs at local retail chains.

  • Sustain Essential Services: Utilize 340B revenue to cross-subsidize non-billable programs like chemotherapy and dental care.

  • Operational Survival: Maintain the "spread" as a vital funding stream for safety net infrastructure.

• Manufacturer Objectives (Accountability)

  • Verify Financial Flow: Use granular data to ensure discounts are reaching patients rather than enriching middlemen.

  • Address Profit Disparities: Target the 72% profit margins on brand drugs to prevent the program from becoming a "hidden tax."

  • Eliminate Inefficiencies: Identify where PBM fees and administrative costs are siphoning off 340B savings.

(Click Here for More Details on Final Transparency Compromise Arguments)

1.2 Structural Financial Risks: Duplicate Discounts and PBMs

A primary driver for state intervention in favor of more transparency appears to be questions over who benefits the most from 340B discounts and ‘duplicate discount’ problems, a systemic communication failure between the state’s Medicaid claims processing network and the proprietary software used by hospitals.

• Under federal law, manufacturers are prohibited from paying both an upfront 340B discount and a backend Medicaid rebate on the same pill. Because these systems do not share real-time patient identifiers, manufacturers often pay twice, leading to displaced rebates projected to cost Illinois managed Medicaid $286 million in 2025 alone.

• A strategic issue for policymakers also involves the role of Pharmacy Benefit Managers (PBMs), which saw heavily negotiated reforms passed last year (Public Act 104-27). When these middlemen retain 340B funds through administrative fees, it creates an even larger issue for policymakers when those funds/discounts fail to reach the patient at the pharmacy counter.

1.3 The Transparency Compromise

To resolve this deadlock, lawmakers introduced House Amendment 2 to House Bill 4327 at the end of the spring session. This amendment shifted the regulatory focus of otherwise ongoing reviews to a one-time study by the Department of Insurance (DOI) to establish a factual baseline. The timeline is highly deliberate: the DOI must report by July 1, 2028, with a law sunset date of 2032, providing a four-year window for the General Assembly to evaluate data regarding how 340B money is being used by hospitals before the mandate expires.

2. Prescription Drug Affordability Board

The strategic intent of the proposed Prescription Drug Affordability Board (PDAB) is to create a permanent mechanism to mitigate the ‘rationing crisis.’ By implementing state-mandated Upper Payment Limits (UPLs), the board seeks to address the retail price surges that force patients to choose between life-saving medication and basic necessities.

2.1 The Pilot Compromise: Narrowing the Scope

PDAB has been advocated over the past several years with no significant momentum, leading to a ‘Pilot Compromise’ (Senate Bill 3496) that significantly narrowed its operational reach to ensure fiscal and legislative viability. The refined parameters include:

• Prioritized Review: The board will focus UPL efforts on the 10 Medicare-negotiated drugs plus a maximum of 2 additional reviews per year.

• Fiscal Guardrails: Operations are restricted to a $750,000 annual budget with a 5-year sunset clause.

• Agency Opt-In: State agencies (HFS/CMS) maintain the authority to bypass limits to protect existing confidential drug rebates, ensuring the state does not inadvertently lose revenue while pursuing retail affordability.

2.2 Economic Impact: Savings vs. Sustainability

The PDAB debate centers on the tension between immediate fiscal relief and the long-term stability of the healthcare supply chain.

• Projected State Savings: Adopting Medicare-aligned rates could yield $192 million in first year savings for state health plans.

• Innovation and Access Risks: Industry critics argue that price ceilings could stifle the R&D pipeline and specifically restrict access to life-saving rare disease treatments.

• The "Pharmacy Desert" Risk: For healthcare providers, the primary concern is that if UPLs fall below a pharmacy’s drug acquisition cost, local pharmacies may stop stocking essential medications. This creates a scenario where a drug is "affordable" on paper but physically unavailable in the community.

Ultimately, the final PDAB proposal passed the House chamber with less than two weeks left in the legislative session and stalled in the Senate, but the arguments raised and negotiations offered in the final House debates will likely be returned to in the next legislative session (click here for more details on the final debate).

Also of note going into future legislative sessions is that both 340B transparency mandates and the PDAB negotiations represent a significant shift in the legislature toward a data-driven drug pricing regime that enhances the regulatory role of the Illinois Department of Insurance.

1. The Transparency in Downcoding Act

Enactment of Senate Bill 3114, the Transparency in Downcoding Act, represents a watershed moment for downcoding reform in Illinois and potentially nationwide. Too often, the economic health of medical practices has been dictated by ‘black box’ algorithms that operate in the shadows of the payer-provider relationship. This legislation signals a fundamental strategic shift, replacing insurer-mandated automation with a transparent, human-centered framework, at least as it applies to medical billing. By securing these protections, physicians have established a baseline of accountability that ensures clinical nuance, not just code-scanning logic, determines the value of physician care.

1.1 The Crisis of "Invisible" Revenue Loss

Automated downcoding, the unilateral reduction of a claim’s service level by an insurer, has evolved into a sophisticated mechanism for revenue erosion. These algorithms frequently ignore the diagnostic complexity of a patient encounter, focusing solely on the final diagnosis. Consider the ‘Chest Pain vs. Acid Reflux’ scenario: a physician must perform an extensive, high-level workup to rule out a life-threatening cardiac event; when the diagnosis is safely concluded as acid reflux, insurers use automated systems to downcode the entire encounter, reimbursing only for the minor final diagnosis while ignoring the intensive resources required to ensure patient safety.

The fiscal toll of this practice is significant. Testimony from Springfield Clinic during the legislative session revealed that their annual downcoded claims quadrupled from 3,000 to more than 12,000 in a single year, despite static patient volume. This resulted in a $500,000 direct revenue loss, further compounded by $375,000 in mandatory overhead: $175,000 for administrative personnel to manage the friction and $200,000 for specialized software to identify and appeal these machine-driven reductions.

1.2 Legislative Evolution and the Human-in-the-Loop Compromise

The journey from the February 2026 introduction on SB3114 to the final Senate Floor Amendment 2 underscores the pragmatic compromises necessary to secure physician protections. While the medical community initially sought a total ban on AI-driven downcoding, we recognized that providing payers with operational flexibility was the only path to a unanimous mandate.

• Reviewer Qualifications

  • SB 3114: Introduced Version (Feb 2026) Must be a Physician of same/similar specialty.

  • SB 3114: Final Negotiated Bill (SFA 2) Natural Person (for determinations); Health Care Professional (APRN, PA, Physician) for disputes.

• Automation Rules

  • SB 3114: Introduced Version (Feb 2026) Total Ban on automated tools/AI for downcoding.

  • SB 3114: Final Negotiated Bill (SFA 2) AI may flag claims; prohibits automation from bypassing human evaluation.

• Appeal Window

  • SB 3114: Introduced Version (Feb 2026) At least 180 days.

  • SB 3114: Final Negotiated Bill (SFA 2) 90 days.

• Notification Details

  • SB 3114: Introduced Version (Feb 2026) Must include decider's NPI and credentials.

  • SB 3114: Final Negotiated Bill (SFA 2) Must provide clinical info and specific CPT coding guidance used.

• Enforcement Nature

  • SB 3114: Introduced Version (Feb 2026) Direct clinical adjudication.

  • SB 3114: Final Negotiated Bill (SFA 2) DOI as "Referee of Process" (verifying natural person review).

1.3 Mechanics of the Final Framework

Starting January 1, 2028, insurers must operate under a "human-in-the-loop" requirement. While AI may flag claims for potential reduction, a "natural person" must review and finalize the downcoding determination. To manage payer costs and ensure the bill's passage, this reviewer pool includes Physicians, APRNs, and PAs. Furthermore, payers must use specific Claim Adjustment Reason Codes (CARC) and Remittance Advice Remark Codes (RARC) that cite exact Current Procedural Terminology (CPT) guidelines.

Critically, the removal of the NPI and credentialing requirement for the initial reviewer shifts the nature of billing disputes. Rather than a peer-to-peer clinical debate over medical necessity, the process is now defined as an administrative policy dispute. This makes the Department of Insurance (DOI) the "referee of process", verifying that the legal steps were followed, rather than a "judge of clinical content."

1.4 Strategic National Implications

The ‘Illinois Model’ leverages operational realities to achieve potential national reach. Approximately 45% of Illinois residents are covered by federal ERISA plans, which are generally exempt from state law. However, national insurers utilize uniform software architectures, so mandated state models, like in Illinois, may result in ‘dual billing systems’ being too administratively burdensome to maintain, thereby creating a de facto national reform as insurers choose administrative simplicity over the cost of maintaining separate automated systems for ERISA plans.

For more details and infographic summaries of the downcoding legislation, Click Here.

While SB 3114 targets the specific economic friction of billing, the 2026 session also established broader guardrails for the underlying technology itself.

2. Artificial Intelligence Proposals & Primary Care Advocacy

The 2026 Illinois legislative session successfully moved some state AI regulation out of the ‘Wild West’ and into a framework of safety and transparency. While billing technology transparency protects physician billing revenue (see Subsection 1 above), other broader AI frameworks started taking shape this year as well, with Illinois at the forefront of Midwest states, and additional healthcare-related AI is likely still to come in the next year.

2.1 Illinois Taking the Lead in the Midwest on AI Accountability

Senate Bill 315, effective January 1, 2027, establishes rigorous oversight for ‘Frontier AI’ developers with over $500 million in revenue. Targeting catastrophic risks, including biological threats and cyberattacks, the bill mandates third-party audits and the publication of safety frameworks. To ensure these are not empty requirements, the Illinois Attorney General has exclusive authority to enforce civil penalties of up to $3 million per violation, seen as essential teeth for a law governing a trillion-dollar industry.

2.2 From Artificial to Augmented Intelligence

IAFP at the state-level, alongside AAFP and AMA at the national-level, is intentionally reframing this technology as "Augmented Intelligence," intended to be more than semantics to focus policy guardrails on AI as assistive, not a replacement for human judgment. Through a ‘Starfield Signal’ approach, advocacy looks for AI that automates clinical memory, summarizing complex histories and spotting patterns so the physician can focus on the person, seen as a potential path toward the ‘Quintuple Aim’.

Advocacy Against the ‘Denial Machine’

This view of augmentation is ultimately threatened by insurer ‘denial machines’, with reports of 1.2-second batch denials and machine error rates as high as 90% being an affront to clinical integrity. While Illinois was one of the first states to pass a comprehensive prior authorization reform with qualified human-in-the-loop requirements and there is federal advocacy for similar prior authorization reform, without additional healthcare guardrails for AI, physicians risk being reduced to data-entry clerks for biased algorithms that prioritize cost-savings over evidence-based care.

Given recent state legislative milestones in downcoding reform against a version of the ‘denial machine’ in medical billing, continued advocacy can help obtain guardrails in other aspects of insurance claim denials, which will be necessary to ensure that the patient-physician relationship remains the center of the healthcare ecosystem, protected from the unmanaged encroachment of automated systems.

1. Expanding Clinical Standards and Access in Women’s Health

Various health equity legislation passing both chambers in the 2026 legislative session represented a strategic evolution in the Illinois healthcare landscape, with a focus on a better understanding of specific patient transitions and modernized clinical protocols to better reflect the diverse needs of patients throughout their life stages.

1.1 The Illinois Menopause Equity and Care Act

The Illinois Menopause Equity and Care Act (House Bill 5284) alters the clinical and administrative treatment of menopause. Effective January 1, 2028, individual and group insurance policies must provide coverage for medically necessary hormonal and non-hormonal therapies. This mandate includes all FDA-approved modalities (oral, transdermal, topical, and vaginal rings) for symptoms and conditions such as vasomotor symptoms and menopause-related osteoporosis.

From a regulatory standpoint, the legislation also amends the Human Rights Act to recognize menopause-related conditions as protected under workplace accommodation rules. Employers may request medical documentation to justify accommodations (e.g. flexible scheduling or climate-adjusted workspaces), provided the request is "job-related and consistent with business necessity"; this places physicians in a position to provide specific medical justifications, including a description of the accommodation, the "medically advisable" date, and the "probable duration." While the insurance mandates take effect in 2028, the Department of Public Health will begin developing educational materials on patient rights and evidence-based treatment options on January 1, 2027.

1.2 New Menopause Educational and Professional Opportunities

Structural changes to medical training and licensure seek to close the knowledge gap in mid-life transitions. Under Senate Bill 3688, all Illinois medical, nursing, and physician assistant schools must integrate menopause and perimenopause management into their core curricula starting January 1, 2027.

Furthermore, Senate Bill 3325 provides a continuing medical education option rather than a mandate. Beginning January 1, 2027, clinicians may utilize menopause-related courses to satisfy the mandatory one-hour implicit bias training requirement for license renewal. This recognizes the clinical nuances of treating aging populations and provides a streamlined path for professional compliance.

1.3 Hormone Therapy Supply Obstacles

To enhance patient adherence and reduce administrative friction, House Bill 5492 requires insurers to cover up to a six-month supply of prescription hormone therapy dispensed at a single time. Effective January 1, 2028, this mandate applies to all drugs used to suppress, increase, or replace hormones (excluding GLP-1 receptor agonists). For therapies classified as controlled substances, insurers must cover the maximum supply allowed under existing State and federal law. This change is designed to eliminate treatment gaps caused by frequent pharmacy visits and prior authorization cycles.

1.4 Advanced Breast Imaging Coverage

House Bill 5001 replaces rigid, age-restricted models with an evidence-based standard for breast cancer screening. Effective January 1, 2028, insurers must cover mammograms and advanced imaging, including ultrasound, MRI, and Molecular Breast Imaging (MBI), based on clinical guidelines (such as those from the National Comprehensive Cancer Network) and provider determination rather than strict age brackets. Notably, MBI must be covered for group policies when a mammogram demonstrates dense breast tissue.

1.5 Contraceptive Autonomy

Regarding reproductive autonomy, Senate Bill 3341, effective January 1, 2027, establishes a significant shift in legal standing: a minor is now deemed to have the same legal capacity to act as an adult for the purpose of consenting to contraceptive services and supplies. This removes the requirement for parental consent and expands access points, explicitly authorizing physicians, APRNs, PAs, and pharmacists to make a “request for prescription contraceptive services or supplies.”

2. Privacy Protections and Information Segregation in Clinical Records

In the current landscape of shifting national health policy, medical privacy has become a paramount concern for Illinois providers. The state has enacted rigorous digital firewalls to serve as a ‘sanctuary’ for sensitive health data, protecting clinicians and patients from the extraterritorial reach of jurisdictions with different legal standards.

2.1 The Reproductive Health Records Privacy Act

Effective July 1, 2027, the Reproductive Health Records Privacy Act, House Bill 5295, mandates that electronic health networks (EHNs) implement technical capabilities to segregate "coded private health care information." This includes diagnostic and procedural codes (CPT, HCPCS, and National Drug Codes) related to abortion care, including mifepristone and multifetal pregnancy reductions, and gender dysphoria.

EHNs are prohibited from disclosing this segregated information to out-of-state entities unless specific consent is obtained. Furthermore, EHNs must develop parsing capabilities to convey general health records while automatically withholding protected data. Crucially, the EHN may not notify out-of-state entities that information has been segregated, preventing the ‘flagging’ of sensitive records.

2.2 De-Scheduling and Purging of Sensitive Prescription Data

With House Bill 4834, effective upon being signed into law by the Governor this summer, Illinois has moved to shield sensitive pharmaceutical data by removing testosterone, estrogen, mifepristone, misoprostol, and GnRH analogues from the state’s Prescription Monitoring Program (PMP). This de-scheduling significantly reduces physician reporting duties for these medications. Additionally, the Department of Human Services is mandated to purge all existing records regarding the prescribing or dispensing of testosterone from the PMP database by January 1, 2027.

IAFP will continue to advocate for a regulatory balance as providers navigate these new digital firewalls under a framework that is intended to protect health equity for vulnerable populations facing federal policy shifts.

3. Streamlining Financial Access for Non-Citizen Healthcare

The correlation between administrative simplicity and the reduction of health disparities is well-documented. For non-citizen and low-income populations, standardized billing is a critical tool for maintaining access to care.

3.1 Uniform Financial Assistance and the Fair Patient Billing Act

House Bill 5390, effective upon being signed into law by the Governor this summer, mandates that the Attorney General adopt rules for a uniform financial assistance form to be used by all Illinois hospitals. By standardizing the application process, the state reduces the confusion and administrative burden that often prevent eligible patients from seeking aid. Under the Act, as amended by the legislation, approval for financial assistance must remain valid for at least 12 months after the first service date, ensuring a stable window of access for patients.

3.2 Strategic Connectivity to State Medicaid Programs

This billing reform, House Bill 5290, is a direct response to federal shifts, specifically the federal policy (HR 1) that eliminated advanced tax credits. This elimination caused a surge in uninsured individuals who lost coverage and turned to state-funded and charitable clinics. By standardizing financial assistance, Illinois seeks to manage this influx and ensure that healthcare remains accessible despite federal subsidies being rescinded.

As physicians manage these billing transitions, they must remain aware of broader state program changes. For comprehensive details on non-citizen Medicaid eligibility and recent coverage changes, refer to the ‘State Medicaid & Related Agency Updates' section of this report, and see below for other ongoing state issues in navigating federal policy changes in recent years.

4. Navigating Federal Friction and State Mandates in Public Health

The Illinois Department of Public Health (IDPH) is currently navigating a federal political storm, characterized by intense friction between state-level science-backed priorities and fluctuating federal recommendations.

4.1 Vaccine Sovereignty and Evidence-Based Practice

Senate Bill 3487, effective January 1, 2027, establishes a legal mechanism for ‘vaccine sovereignty’ in Illinois. It mandates that hospital policies for influenza and pneumococcal immunizations follow "State Guidelines for Communicable Disease Prevention" if federal guidance from the CDC significantly deviates from evidence-based practices established by credible medical communities.

4.2 IDPH Budget Realities and Successes

IDPH is managing a 25% budget reduction following the expiration of federal COVID-19 funds. To protect its mission, the agency is prioritizing "core statutory obligations" and utilizing specialized centers, such as the Center for Minority Health, to expedite grant procurement for Black-led HIV organizations, bypassing traditional administrative delays.

Critically, on March 12th, Illinois secured a preliminary injunction to block the federal government from rescinding $100 million in funding. This victory preserves essential resources for HIV data modernization and services. The efficacy of the state's proactive approach is further evidenced by recent peak comparison data:

• Measles Mitigation: National trends saw a peak of 2,285 cases, while Illinois was limited to 14 cases.

• Vaccine Access: Illinois maintains a 96% student vaccination rate through the Vaccine Access Program.

4.3 Community Safety Initiatives as Public Health Epidemics

For 2026-2027 regulatory focus, IDPH has categorized three core safety issues as public health priorities:

• Lead Poisoning Prevention: The state has lowered the threshold for mandatory state intervention from a 5.0 to a 3.5 blood lead level, triggering mandatory abatement services and inspections in more homes.

• Long-Term Care Oversight: Funded by the Nursing Home Care Act fund, the department is hiring 93 new surveyors to achieve a 1:300 surveyor-to-bed ratio, moving closer to rigorous facility safety goals.

• Violence Intervention: The "Pause to Heal" and safe storage campaigns treat gun violence as a preventable epidemic. These initiatives educate the public on firearm restraining orders, a vital legal tool for patient safety counseling, and have distributed over 100,000 firearm locks.

For more details and an infographic summary of 2026-2027 Illinois Department of Public Health budget and policy priorities, Click Here.

Ultimately, the family physician’s role in navigating a complex, state-led public health landscape is necessary, with continued advocacy opportunities available to IAFP members looking to shape policies in health equity and public health.

1. Scope of Practice Protections

In IAFP’s scope of practice advocacy this session, efforts focused on establishing and defending the statutory boundaries of the medical profession, ensuring that clinical complexity is managed by those with the most rigorous training, while also understanding the importance of efficient medical care for patients in integrated settings.

1.1  Defeating Physician Assistant Independent Practice

The preservation of a physician, team-based care model remains a cornerstone of IAFP legislative strategy. During this session, we successfully helped defeat Senate Bill 3421, a direct assault on the collaborative care model. This legislation sought to grant Physician Assistants (PAs) independent practice after completing minimal continuing education and clinical training. In defeating the legislation, IAFP and physician advocates neutralized the proponents' arguments by highlighting the absence of any substitute for the 10,000+ hours of clinical training physicians undergo, and further demonstrated that similar scope expansions in other states have not increased access to care in rural or underserved areas. It should be noted that while SB 3421 failed to pass this session, its legislative committee traction in favor of PAs signals that independent practice remains the top priority for PAs, so will require sustained advocacy to ensure patient safety protections are not traded away in the future.

1.2 Scope Expansions in Integrated Healthcare

IAFP remains open to scope adjustments that enhance system efficiency without compromising safety. This session, we successfully navigated several expansions where IAFP was supportive or neutral:

• House Bill 3392 (Assisted Living Assessments): Effective upon being signed into law by the Governor this summer, this bill expands the role of PAs and Advanced Practice Registered Nurses (APRNs) by allowing them to conduct initial comprehensive assessments of prospective residents, and physicians did secure a critical safeguard: annual assessments or those triggered by a significant change in condition must still be signed by a physician. Physicians also should note a new administrative risk: repeated technical infractions of these assessments within a calendar year may now result in a Type 3 violation.

• House Bill 4247 (Emergency Medication Administration): Subject to state fiscal year 2027 funding, this legislation expands the definition of "trained personnel" to include coaches and athletic trainers. It allows these individuals to administer undesignated asthma medication or epinephrine injectors in school settings. This expansion is designed to ensure immediate response to respiratory distress or anaphylaxis during interscholastic activities.

• House Bill 4793 (Pharmacy Ancillary Equipment): Effective January 1, 2027, this bill updates responsibilities within pharmacy practice, specifically regarding the handling and dispensing of ancillary durable medical equipment by pharmacy staff under the supervision of a pharmacist.

• Senate Bill 3213 (Prescription Transfers): Effective January 1, 2027, pharmacies are now mandated to transfer prescriptions (including Schedule II-V) at a patient’s request if the prescription was received but not yet filled; furthermore, licensed pharmacy technicians may now perform these transfers if delegated by a pharmacist, all of which is intended to reduce the administrative delay for patients seeking to fill prescriptions at their preferred location.

1.3 Emerging Models: "Text-a-Physician" Programs

The introduction of House Bill 5772 at the end of the legislative session represents a newer competitive frontier of healthcare access: asynchronous, text-based healthcare services. This bill allows municipalities to contract for services that include providing physician notes for work and school via text, which poses potential issues for the traditional family medicine office visit and the established patient-physician relationship. It should be noted that home rule communities in Illinois already appear authorized to engage this model in their cities (see e.g. Village of Algonquin), so the legislation would impact the significant number of non-home rule municipalities.

Framework for Negotiation

To protect the standard of care, IAFP is looking for continued member engagement in the formation of policy guardrails for any state legislative authorization of such programs in non-home rule communities, e.g.:

• Prescribing Restrictions: Strict limits on medications that can be prescribed via text without a prior, established clinical relationship.

• Required Encounter Summaries: Mandatory generation of summaries to be sent to the patient’s primary care physician to maintain continuity and prevent care fragmentation.

2. PMP Compliance and Substance Scheduling

The evolving regulatory landscape of controlled substances requires a delicate balance between public oversight and clinical reality. Streamlining substance scheduling and clarifying liability for the Prescription Monitoring Program (PMP) are vital for reducing physician burnout while maintaining a high standard of patient safety.

2.1 New PMP Requirements

House Bill 5148 reflects intermittent negotiations over the past several years regarding an Illinois Department of Human Services (DHS) initiative in response to a poor 2021 state audit of DHS’s PMP oversight. This spring, a compromise was reached, effective January 1, 2027, that requires prescribers to review patient access to controlled substances using the PMP when writing an initial prescription for Schedule II stimulants, all Schedule II opioids, and all Schedule IV benzodiazepine. An exemption from liability and professional discipline was also secured for physicians in instances where technological or electrical failures prevent PMP access.

2.2 Streamlining Substance Scheduling

To reduce state-level delays and resulting confusion in controlled substance schedule changes, Senate Bill 3322, effective upon being signed into law by the Governor this summer, mandates that Illinois automatically mirror federal scheduling changes for controlled substances within 30 days of federal schedule changes.

3. Reporting, Disclosures, and Organizational Oversight

This legislative cycle saw an increase in transparency mandates, some of which may ultimately be beneficial if resulting in more recognition of the value of primary care. However, while these measures often aim to protect patients and healthcare workers, they sometimes represent a considerable administrative burden for family physicians and medical directors who must oversee a complex web of reporting and identification requirements.

3.1 Clinical and Patient Disclosures

Additional transparency at the point of care:

• House Bill 4698 (Additional Fee Disclosure): Effective January 1, 2027, physicians must obtain written acknowledgment from patients regarding separate billing for wellness visits when additional medical issues are encountered during the same encounter.

• House Bill 3169 (Child Abuse Investigations): Effective January 1, 2027, this bill mandates additional disclosures to a parent or guardian regarding the role of a child abuse pediatrician in a Department of Children and Family Services investigation.

3.2 Safety and Misconduct Reporting (HB 3711 & SB 2713)

• House Bill 3711 (Health Professional Sexual Misconduct): Effective January 1, 2027, this legislation requires health professionals to report witnessed or reported misconduct to the Department of Financial and Professional Regulation (IDFPR) within 24 hours. Of note, the definition of ‘Intimate Conduct’ includes demeaning sexual comments, neglect in disrobing or draping practices, and ‘romantic’ kissing, and the trigger includes ‘reasonable cause to believe’. The legislation is the result of criminal abuse by a Chicago gynecologist found guilty in 2021.

• Senate Bill 2713 (Workplace Violence Prevention): Effective January 1, 2027, enhancements to the Health Care Violence Prevention Act will require Emergency Departments to maintain detailed logs of ‘Type 2’ violent incidents, and protections against obstacles to health professionals reporting violent workplace incidents.

3.3  Structural Oversight and Professional Standards

• House Bill 5000 (Anti-Trust Merger Notice): Effective January 1, 2027, this legislation extends the otherwise sunsetting healthcare merger notification requirement permanently (i.e. 30-day notice to the Attorney General). A permanent role for state oversight is a result of the rise of private equity in medicine, and in particular, there is a growing regulatory focus on transactions involving indirect ownership and private equity company owners. Further legislative and regulatory advocacy in this area may also involve consideration of work done in other states and related national model laws (see e.g. National Academy for State Health Policy).

• Workers’ Comp Reform (Utilization Review): Effective upon being signed by the Governor this summer, House Bill 5228 includes a victory for physicians who have a higher volume of workplace injury-related care. Utilization Review (UR) and Independent Medical Examination (IME) standards will now require the reviewer to hold an unrestricted U.S. license and be of the same specialty as the treating physician.

IAFP remains committed to monitoring the implementation of any mandates, with a priority on ensuring that while transparency and safety are achieved, these requirements do not exacerbate the administrative burdens that lead to physician burnout or disrupt the delivery of high-quality patient care.

IAFP Legislative Workgroups

Through engagement with the IAFP Government Relations Committee, members are already working on policy guidance regarding several subject areas relevant to family physicians that are seeing ongoing legislative and regulatory considerations, including the following:

• Artificial Intelligence

• Menopause Equity

• Text-A-Physician

• Non-Compete Clauses

Additional legislative workgroup opportunities are likely over the next year, in addition to input in drafting formal public comment in the rulemaking process for many of the above detailed legislation that passed the legislature this spring.

Advocacy Elective

With ACGME recognition of advocacy as a core competency, IAFP can help residency programs provide a unique educational opportunity. Each of the last few years have resulted in residency programs providing family medicine residents a one-on-one engagement opportunity with IAFP’s lobbyist during their elective period.

Spring into Action

Another unique advocacy opportunity every two years is IAFP’s Spring into Action, which brings over 100 family physician colleagues to the state capitol to see the legislative process firsthand and personally speak to policies impacting primary care. Stay tuned for more information and likely save-the-date for early April.

For questions, to learn more, or to get involved, email Gordana Krkic, CAE, Chief Executive Officer and Chief Advocacy Officer gkrkic@iafp.com.